$CLPT

BURNETT JOSEPH sold $1.1M of CLPT

BURNETT JOSEPH (CEO and President) sold 60,000 shares of ClearPoint Neuro, Inc. (CLPT) at $17.79 ($1.07M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BURNETT JOSEPH
Published Jun 22, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLPT
Neutral
medium confidence
Mentioned
$CLPT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale of 60,000 shares at a stated price, with holdings after the transaction and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing reduces the likelihood of a durable negative fundamental interpretation.

03

What to watch

The filing does not indicate whether other insiders or the company announced concurrent catalysts; without follow-on news, the signal is mostly sentiment/positioning rather than fundamentals.

Relevance 5/10Novelty 5/10Timing: Form 4 filed June 22 (sale dated June 17)

Background

The article is an SEC Form 4 insider transaction disclosure for ClearPoint Neuro, Inc. (CLPT).

Company-level read

Ticker impact

$CLPTNeutralMedium confidence
Context

ClearPoint Neuro CEO Joseph Burnett sold 60,000 shares at $17.79 under a 10b5-1 plan, disclosed via Form 4 filed June 22.

Expected impact

Likely limited near-term price impact; any reaction should fade unless accompanied by other news.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

No clear sector read-across; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations; traders may overreact to the headline sale size.

Key entities

  • ClearPoint Neuro, Inc.

    Issuer of the Form 4 insider transaction; CEO Joseph Burnett sold shares under a 10b5-1 plan.

  • Joseph Burnett

    CEO and President; reported open-market sale of 60,000 shares on June 17, 2026.

Related articles

$CLPTMed

ClearPoint Neuro, Inc. (CLPT): Results of Operations and Financial Condition

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, In